Clik here to view.
Medical Advisory #423: CSL Behring Discontinues Production and Distribution...
CSL Behring Discontinues Production and Distribution of Monoclate-P®Read more about Medical Advisory #423: CSL Behring Discontinues Production and Distribution of Monoclate-P®Log in or register to post...
View ArticleAptevo Announces Patient-Reported Study Results Related to IXINITY® Use
Aptevo Therapeutics recently announced patient-reported data on individuals currently being treated with IXINITY®, the company’s recombinant factor IX product. IXINITY® is indicated for the control and...
View ArticleNew Medscape Activity Describes Latest Advances in Inhibitor Management
“Advances in Managing Inhibitors in Patients with Hemophilia A,” is the newest educational opportunity to become available through Medscape. It is intended for hematologists, pediatricians, nurses and...
View ArticleClik here to view.
Recent Questions Surrounding Hemlibra
NHF received information from Genentech’s Clinical Development Lead regarding reports of the death of patients utilizing Hemlibra (emicizumab).Read more about Recent Questions Surrounding Hemlibra
View ArticleNew Inhibitor Screening Kit Unveiled at THSNA
Rockville, Maryland-based Precision BioLogic is collaborating with Roche and Genentech on the development of a new diagnostic kit for inhibitor testing of individuals with hemophilia A. The modified...
View ArticleClik here to view.
Statement from Genentech Regarding Hemlibra
Updated statement from Genentech on Hemlibra, March 28, 2018.Read more about Statement from Genentech Regarding Hemlibra
View ArticleClik here to view.
Apply Today for the 2018 Kevin Child Scholarship!
Applications are now open! The selected KCS recipient will receive an award of $1,000 toward their tuition costs.Read more about Apply Today for the 2018 Kevin Child Scholarship!
View ArticleClik here to view.
NHF 70th: The Fight to Preserve ACA Patient Protections Goes On
2018 marks NHF’s 70th year as the bleeding disorders community’s chief advocate.Read more about NHF 70th: The Fight to Preserve ACA Patient Protections Goes On
View ArticleClik here to view.
NHF CEO Shares Vision with Chapters
Val D. Bias spoke to the leaders of NHF’s 52-chapter networks at the NHF 2018 Chapter Leadership Seminar in San Francisco, California.Read more about NHF CEO Shares Vision with Chapters
View ArticleClik here to view.
Grifols Announces 2017 Factor Product Donations to WFH Humanitarian Aid Program
The company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B.Read more about Grifols Announces 2017 Factor Product Donations to WFH Humanitarian Aid...
View ArticleClik here to view.
ICER Review of Emicizumab for People with Hemophilia A and Inhibitors
ICER is an independent and non-partisan research organization that evaluates the clinical and economic value of prescription drugs, medical tests, and other healthcare and healthcare delivery...
View ArticleClik here to view.
Envisioning “Treatment for All” on World Hemophilia Day
NHF is expanding its work with the bleeding disorders community around the world.Read more about Envisioning “Treatment for All” on World Hemophilia Day
View ArticleClik here to view.
HEMLIBRA® Receives Breakthrough Designation from FDA
The designation is for people with hemophilia A without inhibitors.Read more about HEMLIBRA® Receives Breakthrough Designation from FDA
View ArticleClik here to view.
MASAC Issues New Treatment Recommendation
NHF's MASAC has issued the latest revision to their most comprehensive treatment document.Read more about MASAC Issues New Treatment Recommendation
View ArticleClik here to view.
MASAC Safety Information Update on Emicizumab (HEMLIBRA)
Emicizumab-kxwh (HEMLIBRA, Genentech) was approved for use by the US Food and Drug Administration on November 16, 2017 for individuals with hemophilia A and inhibitors.Read more about MASAC Safety...
View ArticleVONVENDI® Receives Expanded FDA Approval for Surgery in VWD Patients
Shire recently announced that the U.S. Food and Drug Administration (FDA) has approved the company’s recombinant von Willebrand factor (rVWF) product VONVENDI®, for perioperative management of bleeding...
View ArticleHANDI Highlights Healthy Living Resources to the Community
There is no time like Spring and its milder temps, to get re-energized and become an engaged steward of your health through exercise and nutrition. The National Hemophilia Foundation (NHF)’s...
View ArticleClik here to view.
Study Suggests Prophylaxis Could Reduce Hospitalizations for VWD Patients
The study investigated the frequency of hospital admittances for people with VWD to determine if the implementation of a prophylactic treatment regimen is associated with a reduction in...
View ArticleClik here to view.
Patient Education Leads to Drop in Prosthetic Joint Infections
OIC study suggests that enhanced education on intravenous self-infusion of factor therapy can significantly reduce prosthetic joint infections for hemophilia patients.Read more about Patient Education...
View ArticleClik here to view.
NHLBI Workshop on Factor VIII Inhibitors is Less Than Two Weeks Away!
The workshop aims to solicit hemophilia community-wide input into a coordinated national blueprint for future research on factor VIII immunogenicity and factor VIII inhibitor prevention and...
View Article